Skip to content

EUS guided RFA for the management of pancreatic and peripancreatic tumor; efficacy and safety evaluation

EUS guided RFA for the management of pancreatic and peripancreatic tumor; efficacy and safety evaluation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002467
Enrollment
25
Registered
2017-09-15
Start date
2016-10-21
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : The RFA (EUSRA) procedure varies depending on the disease and symptoms, but typically takes between 30 minutes and 1 hour, and carries a total of one to five times. Additional procedu

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Persons who are able to understand clinical trials of Adults under the age of 20 and under 80 years old who are voluntarily agreed to participate in this clinical trial, voluntarily agreeing to sign consent for this clinical trial. 2. Patients who have been diagnosed with tumors of pancreas and pancreatic tumors using biopsy. 3. Estimated expectation period of 6 months or more. 4. Patients who are inoperable and can not be Received radiation therapy due to a lack of immunity. 5. Patients who do not respond to existing anti-cancer drugs and radiation therapy 6. cancer patient is examined by CT or MRI 7. Patients with = 50 % of Karnofsky performance status 8. Patient whose results are normal in the blood coagulation test 9. Female of child bearing age must have negative results in pregnancy examinations.. 10. Patients who follow the clinical trial procedure and comply with the visit schedule. 11. Patients should not have physiological, family-oriented, social, or geographical conditions that do not permit medical tracking surveys and compliance with this clinical trial.

Exclusion criteria

Exclusion criteria: 1. Patient who can not see images of endoscopic ultrasonography. 2. Patients with an obstruction in the endoscopy path 3. disseminated intravascular coagulation 4. Patients who are taking drugs that can cause bleeding, such as aspirin.. 5. Chronic obstructive or restrictive chronic lung disease, including breathing difficulty during recess 6. Other serious diseases or medical conditions. 7. Pregnant women, breastfeeding women, and women of child bearing age who don't use proper contraception. 8. Other medical condition that may impair the ability of patients to participate in clinical trials. 9. Patients with significant neurologic or psychiatric disorder, such as dementia or strokes. 10. Despite the treatment unstable heart disease, a heart attack occurs within six months prior to the clinical trial (Even if a heart attack is diagnosed within six months prior to the clinical trial, a heart condition that remains stable is possible for enroll the study.)

Design outcomes

Primary

MeasureTime frame
Assessment of changes in the size of pancreatic tumours in CT or MRI

Secondary

MeasureTime frame
Evaluation of pain level by treatment using pain assessment tool ;Assessment of complications based on treatment via CT/MRI, blood tests and abnormal reactions.

Countries

Korea, Republic of

Contacts

Public Contacthyeonji kang

Asan Medical Center

amckanghj4@daum.net+82-2-3010-1067

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026